HOUSTON — The first complete results from placebo-controlled trials of cannabidiol in Lennox-Gastaut and Dravet syndromes were presented at the 2016 American Epilepsy Society Annual Meeting

Elizabeth Thiele, MD, PhD, a lead investigator on the Lennox-Gastaut trial, sat down with Neurology Advisor to discuss the results from the first placebo-controlled study, in which treatment with cannabidiol reduced the frequency of drop seizures in patients with treatment-resistant Lennox-Gastaut who were taking concomitant AEDs. 

To read the full article, go here